IP Library Granted Patent US 8,426,675
Granted Patent B2
US 8,426,675 · App. 13/155,087 · Granted Apr 23, 2013

Methods for producing microRNAs

Inventors: Ross Dickins (Carlton, AU); Scott W. Lowe (Cold Spring Harbor, NY); Gregory J. Hannon (Huntington, NY)
Assignee: Cold Spring Harbor Laboratory
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,426,675
App. No.
13/155,087
Granted
Apr 23, 2013
Kind
B2
Abstract

The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.

Claims (7)

1. A non-human mammal comprising a population of cells, wherein each cell in said population harbors only a single, stably integrated copy of a nucleic acid construct for expression of a synthetic miR30-based shRNA, wherein said construct contains only a single tetracycline responsive RNA Polymerase II (Pol II) promoter operably linked to a sequence encoding only a single synthetic mir30-based shRNA directed against a target gene, wherein in said population of cells, induced expression of the synthetic miR30-based shRNA is sufficient to inhibit expression of the target gene by at least about 80%.

2. The non-human mammal of claim 1 , wherein the promoter comprises a tet-off promoter, such that the synthetic miR30-based shRNA is expressed in the absence of tetracycline or a tetracycline analog.

3. The non-human mammal of claim 1 , wherein the promoter comprises a tet-on promoter such that the synthetic miR30-based shRNA is expressed when the mammal is treated with tetracycline or a tetracycline analog.

4. The non-human mammal of claim 1 , 2 or 3 , wherein the population of cells further comprises an additional nucleic acid construct encoding tetracycline-controlled transactivator (tTA) or reverse tetracycline-controlled transactivator (rtTA).

5. The non-human mammal of claim 1 , 2 or 3 , wherein the population of cells further comprises an additional nucleic acid construct encoding Cre recombinase.

6. The non-human mammal of claim 1 , 2 or 3 , wherein the single tetracycline responsive RNA Polymerase II (Pol II) promoter is a LoxP-stop-LoxP system promoter.

7. The non-human mammal of claim 1 , 2 or 3 , which is a chimeric mammal, whose somatic or germ cells comprise said population of cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 4, 2017
From: COLD SPRING HARBOR LABORATORY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044680/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2011
From: DICKINS, ROSS; HANNON, GREGORY J.; LOWE, SCOTT W.
To: COLD SPRING HARBOR LABORATORY
Reel/Frame 026407/0552 →
Continuity (4)
Division 12156957 · Jun 5, 2008
Continuation 11444107 · May 31, 2006
Provisional Application 60686135 · May 31, 2005
Related Publication 20120084872A1 · Apr 5, 2012